Christoph B. Olivier,Marius Wessinger/LinkedIn
Mar 13, 2026, 20:11
Christoph B. Olivier: New Research from Marius Wessinger on Predicting Therapy Success After Pulmonary Embolism
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared on LinkedIn, adding:
”As the Principal Investigator of this study, Marius Wessinger is sharing new insights on ‘Hemostatic Profiling of Patients after Pulmonary Embolism to Predict Success of Different Therapy Options.’
His work focuses on leveraging TEG analysis to assess hemostatic profiles, aiming to provide more personalized and efficient therapy paths for patients at intermediate-risk.
It is inspiring to see how our team’s dedication translates into clinical evidence that could improve patient outcomes.
Great job, Marius!”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS